Accredo Health (ACDO) is in the process of buying Gentiva's Specialty Pharmaceutical Services (SPS) for $492 million, half in cash and half in Accredo stock. The SPS part of Gentiva accounts for half of their annual sales, has the higher net margin, and is the faster growing part of Gentiva. Accredo only wants the chronic medication part of the business and will rid itself of the acute business by the end of this year. Will Accredo sale the acute business back to Gentiva or will Gentiva simply be a home health nursing company? Does this answer your question?
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar